NEXT Financial Group Inc Sells 341 Shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

NEXT Financial Group Inc lowered its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 3.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 10,812 shares of the financial services provider’s stock after selling 341 shares during the quarter. NEXT Financial Group Inc’s holdings in iShares Nasdaq Biotechnology ETF were worth $1,076,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of IBB. Global Trust Asset Management LLC grew its holdings in iShares Nasdaq Biotechnology ETF by 89,733.3% during the second quarter. Global Trust Asset Management LLC now owns 32,340 shares of the financial services provider’s stock valued at $32,000 after purchasing an additional 32,304 shares during the period. Signaturefd LLC grew its holdings in iShares Nasdaq Biotechnology ETF by 59.2% during the second quarter. Signaturefd LLC now owns 328 shares of the financial services provider’s stock valued at $36,000 after purchasing an additional 122 shares during the period. HM Payson & Co. bought a new stake in iShares Nasdaq Biotechnology ETF during the second quarter valued at about $36,000. Oakworth Capital Inc. grew its holdings in iShares Nasdaq Biotechnology ETF by 171.4% during the second quarter. Oakworth Capital Inc. now owns 475 shares of the financial services provider’s stock valued at $52,000 after purchasing an additional 300 shares during the period. Finally, Doyle Wealth Management bought a new stake in iShares Nasdaq Biotechnology ETF during the second quarter valued at about $52,000. 78.34% of the stock is owned by institutional investors.

NASDAQ:IBB opened at $102.27 on Friday. The stock has a 50-day simple moving average of $101.83 and a two-hundred day simple moving average of $105.04. iShares Nasdaq Biotechnology ETF has a 52-week low of $89.01 and a 52-week high of $116.25.

The business also recently declared a — dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were issued a dividend of $0.0715 per share. This represents a yield of 0.1%. The ex-dividend date was Tuesday, September 24th.

Separately, ValuEngine raised iShares Nasdaq Biotechnology ETF from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.